ÂÜÀòÂÒÂ×

Andrew Jefferson has a strong background in the biotechnology industry, primarily in Chief Operating Officer roles. Andrew has held this position at multiple companies, including Bright Peak Therapeutics AG, Vector BioPharma AG, Ridgeline Discovery, Matterhorn Biosciences AG, Cimeio Therapeutics AG, RedRidge Bio AG, and Granite Bio AG. Andrew is currently serving as a Board Member at Nouscom AG and an Operating Partner at Versant Ventures.

Andrew Jefferson attended the University of Nottingham from 1987 to 1990, where they obtained a BSc (Hons) degree in Chemistry. Andrew later pursued an MBA in Business Administration at the University of Brighton from 1995 to 1999.